Search publications

Publications

  • Benitez-Ribas D, Cabezón R, Flórez-Grau G, Molero MC, Puerta P, Guillen-Quesada A, Paco-Mercader S, Carcaboso AM, Santa-Maria Lopez V, Cruz-Martínez O, de Torres C, Salvador N, Juan M, Mora J and Morales-La Madrid A.

    Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

    Frontiers in oncology . 8: 127-127. Number of citations: 31

    [doi:10.3389/fonc.2018.00127]

  • Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popovic M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE and Suvà ML.

    Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq

    SCIENCE . 360(6386): 331-335. Number of citations: 415

    [doi:10.1126/science.aao4750]

  • Royer-Pokora B, Beier M, Brandt A, Duhme C, Busch M, de Torres C, Royer HD and Mora J.

    Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors

    CANCER MEDICINE . 7(4): 1359-1368. Number of citations: 9

    [doi:10.1002/cam4.1379]

  • Mora J, Pérez-Jaume S and Cruz-Martínez O.

    Treatment of childhood astrocytomas with irinotecan and cisplatin

    CLINICAL & TRANSLATIONAL ONCOLOGY . 20(4): 500-507. Number of citations: 3

    [doi:10.1007/s12094-017-1741-z]

  • Gomez-Gonzalez S, Garrido- García A, García-Gerique L, Lemos I, Suñol M, de Torres C, Kulis M, Pérez-Jaume S, Carcaboso AM, Luu B, Kieran MW, Jabado N, Kozlenkov A, Dracheva S, Ramaswamy V, Hovestadt V, Johann P, Jones DTW, Pfister SM, Morales-La Madrid A, Cruz-Martínez O, Taylor MD, Martín-Subero JI, Mora J and Lavarino C.

    A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma

    CLINICAL CANCER RESEARCH . 24(6): 1355-1363. Number of citations: 22

    [doi:10.1158/1078-0432.CCR-17-2243]

  • Prieto C, López-Millán B, Roca-Ho H, Stam RW, Romero-Moya D, Rodríguez-Baena FJ, Sanjuan-Pla A, Ayllón V, Ramírez M, Bardini M, De Lorenzo P, Valsecchi MG, Stanulla M, Iglesias M, Ballerini P, Carcaboso AM, Mora J, Locatelli F, Bertaina A, Padilla L, Rodríguez-Manzaneque JC, Bueno C and Menéndez P.

    NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL

    Leukemia . 32(3): 633-644. Number of citations: 29

    [doi:10.1038/leu.2017.294]

  • Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, Kwiatkowski N, Zhang T, Abraham BJ, Mora J, Kalev P, Leggett A, Chowdhury D, Benes CH, Young RA, Gray NS and Stegmaier K.

    EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

    Cancer Cell . 33(2): 202-216. Number of citations: 115

    [doi:10.1016/j.ccell.2017.12.009]

  • Krauel L, De Haro-Jorge I, Carrasco-Torrents R, Vancells M and Mora J.

    Upfront Nephrectomy for the Treatment of Wilms Tumor: Outcomes and Predictors of Complications

    Journal of Child Science . 8: 21-26.

    [doi:10.1055/s-0038-1641149]

  • Ding YY, Panzer J, Maris JM, Castañeda-Heredia A, Gómez-Chiari M and Mora J.

    Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

    PEDIATRIC BLOOD & CANCER . 65(1): . Number of citations: 19

    [doi:10.1002/pbc.26732]

  • Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N and Lopez-Pousa A.

    Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

    ANNALS OF ONCOLOGY . 28(12): 2994-2999. Number of citations: 48

    [doi:10.1093/annonc/mdx536]